Clinical trials: ARDS (Moderate or Severe)
ARDS (Moderate or Severe), Adult Patients
Role of Elastic Power in Acute Respiratory Distress Syndrome
Mechanical ventilation is essential for managing acute respiratory distress syndrome (ARDS), but it can also cause ventilator-induced lung injury (VILI) due to mechanical forces.
- Trial name
- NCT06878313
- Volunteers
- 20 people
- Sponsor
- Hospital El Cruce
Acute Respiratory Distress Syndrome, Infections
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS…
- Trial name
- NCT05947955
- Testing
- Rhu-pGSN, normal saline
- Where
- 65 sites in United States, Belgium and 11 more
- Volunteers
- 600 people
- Sponsor
- BioAegis Therapeutics Inc.
ARDS (Moderate or Severe), AHRF
STimulation to Activate RespIration
Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute…
- Conditions
- ARDS (Moderate or Severe), AHRF, Mechanically Ventilated ICU Patients
- Trial name
- STARI (NCT06832306)
- Testing
- Phrenic Nerve Stimulation
- Where
- 7 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Lungpacer Medical Inc.
ARDS, Human
Effect of Electric Impedance Tomography-Guided PEEP Titration
Acute respiratory syndrome distress (ARDS) is a clinical common syndrome with high mortality. Mechanical ventilation (MV) is the cornerstone of management of ARDS but can lead to ventilator-induced lung injury.
- Trial name
- NCT05736185
- Testing
- PEEP selection
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Southeast University, China
ARDS (Moderate or Severe), ARDS (Acute Respiratory Distress Syndrome)
A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome
This study is a randomized, blank-controlled, open-label, single-dose, dose-escalation clinical study of rhKGF-2 in patients with ARDS.
- Trial name
- NCT07558538
- Testing
- Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Zhongshan Hospital
ARDS (Moderate or Severe)
Combining Electrical Impedance Tomography and Thoracic Ultrasound Toinvestigate Dynamic Changes
1. To evaluate the dynamic changes of lung ultrasound during electrical impedance tomography (EIT) PEEP titration and across the first week of ARDS. 2.
- Trial name
- NCT06958770
- Testing
- Electrical impedance tomography
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
ARDS (Moderate or Severe)
Prone Positioning in ARDS: Predicting Neurological Complications Via Cerebral Hemodynamics
Prone Positioning in ARDS: Predicting Neurological Complications via Cerebral Hemodynamics
- Trial name
- PRONEBRAINAR (NCT06967285)
- Testing
- Prone ventilation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sichuan Provincial People's Hospital
ARDS (Moderate or Severe), Prone Position
The PRE-VAIL Study
During the prone position, there may be an increase in intragastric pressure. The investigators focus on a scientific question: Whether reducing enteral nutrition before the prone position will benefit patients with severe…
- Conditions
- ARDS (Moderate or Severe), Prone Position, Enteral Nutrition Feeding, Intensive Care Unit (ICU) Admission
- Trial name
- NCT07176624
- Testing
- Enteral nutrition is reduced before the prone position
- Where
- China
- Volunteers
- 259 people
- Sponsor
- The First Hospital of Jilin University
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
ARDS (Moderate or Severe), Acute Hypoxemic Respiratory Failure
PEEP-induced Effects on Respiratory dRivE and EFfort
Rationale: In patients with acute hypoxemic respiratory failure (AHRF), preserving spontaneous breathing during mechanical ventilation offers physiological benefits, but also carries risks.
- Trial name
- REEF (NCT07203781)
- Testing
- PEEP level changes
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with…
- Conditions
- COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04565665
- Testing
- Best Practice, Mesenchymal Stem Cell
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
ARDS (Moderate or Severe)
FAPI PET/CT to Detect Fibroblast Activity in Non-resolving ARDS
Of patients requiring mechanical ventilation in the ICU 23% meet criteria of the Acute Respiratory Distress Syndrome (ARDS). Mortality of this syndrome remains high (35-46%) in moderate and severe ARDS.
- Trial name
- FAPI ARDS (NCT06691464)
- Testing
- PET
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
ARDS (Moderate or Severe)
Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS
To verify whether the transpulmonary pressure-guided mechanical ventilation strategy can reduce right ventricular involvement, especially the incidence of acute cor pulmonale (ACP), in patients with moderate to severe ARDS…
- Trial name
- NCT07490925
- Testing
- Transpulmonary pressure guided mechanical ventilation strategy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Beijing Chao Yang Hospital
Covid19, Cytokine Release Syndrome
Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan
Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19) and related pneumonia, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Investigators have seen…
- Conditions
- Covid19, Cytokine Release Syndrome, Critical Illness, ARDS
- Trial name
- NCT04492501
- Testing
- Therapeutic Plasma exchange, Convalescent Plasma, Tocilizumab
- Where
- Pakistan
- Volunteers
- 600 people
- Sponsor
- UNICEF
Respiratory Distress Syndrome, Adult
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) is compared to placebo. Investigation is conducted with patients who have acute respiratory distress syndrome (ARDS).
- Trial name
- INTEREST (NCT02622724)
- Testing
- Interferon beta-1a
- Where
- 71 sites in Belgium, Czechia and 6 more
- Volunteers
- 301 people
- Sponsor
- Faron Pharmaceuticals Ltd
ARDS (Moderate or Severe)
Effect of Inhaled Nitric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Distress Syndrome
The goal of this clinical trial is to evaluate whether inhaled nitric oxide (iNO), added to standard care, can reduce mortality in adults with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- ENARCT-ARDS (NCT07334873)
- Testing
- Inhaled Nitric Oxide Therapy
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe)
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2…
- Conditions
- Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
- Trial name
- NCT04466098
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota